# Olvimulogene nanivacirepvec

Source: https://onco.cc/drugs/olvimulogene-nanivacirepvec/  
OnCo record `olvimulogene-nanivacirepvec` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Olvimulogene nanivacirepvec is an experimental oncolytic virus from Genelux in phase 3 trials for ovarian cancer and non-small-cell lung cancer, with its target not yet stated publicly.

## Summary

Olvimulogene nanivacirepvec is an oncolytic virus developed by Genelux. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Olvi-Vec is an engineered oncolytic vaccinia virus. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)), in ovarian cancer and non-small-cell lung cancer. The largest, NCT05281471, plans to enrol 186 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: GL-ONC1 and GLV-1h68; Olvi-Vec; GL-ONC; GLV-1h68
- Tags: pipeline; ctgov-ingest
- Modality: oncolytic virus
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of Olvimulogene nanivacirepvec: https://clinicaltrials.gov/search?intr=Olvimulogene%20nanivacirepvec
- Sponsor page: https://www.genelux.com

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Genelux](https://onco.cc/companies/genelux/)
- trials: [Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)](https://onco.cc/trials/nct05281471/), [Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ](https://onco.cc/trials/nct06463665/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)

---
JSON: https://onco.cc/api/v1/entities/olvimulogene-nanivacirepvec.json